|
|
|
|
|
Welcome to the Broad Institute newsletter. Learn about a new project studying how stress, trauma, and adversity impact the body at the cellular and molecular level. A cancer drug candidate based on Broad science is under review at the FDA. Read about how the compound works in lung cancer models.
|
|
|
|
New research collaboration aims to understand how adverse life experiences affect human biology and increase risk of health disorders. LEARN MORE
|
|
|
|
Whole human genome sequencing and analysis was completed in less than 4 hours, surpassing the previous benchmark of 5 hours and 2 minutes. LEARN MORE
|
|
|
|
The compound, now under priority review at FDA, targets HER2 mutations in lung cancer and shrinks tumors in mice and humans. LEARN MORE
A single mutation in the CD36 gene, present in 17 percent of people with African ancestry, increases a person's dilated cardiomyopathy risk by 33 percent. LEARN MORE
|
|
|
|
The time and cost of whole genome sequencing has dropped so much over the last 20 years that it could soon be part of everyone's medical care. What could that mean for the future of our health?
Join Niall Lennon of Broad Clinical Labs on Wednesday, November 19 at 6:00 pm ET for a conversation about what the intersection of medical genomics, precision medicine, and preventive healthcare could mean for you. Register for this free, in-person/livestreamed event.
|
|
|
Thank you for reading!
We're always looking for feedback; email us at newsl...@broadinstitute.org.
Please forward this email to your friends and colleagues.
Was this email forwarded to you?
|
|
|
|
|
|
|
|
|
|
|
